prof. Vibeke Kruse

Journal Article

Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors The CHEERS Phase 2 Randomized Clinical Trial

Mathieu Spaas (UGent) , Nora Sundahl, Vibeke Kruse (UGent) , Sylvie Rottey (UGent) , Daan De Maeseneer (UGent) , Fréderic Duprez (UGent) , Yolande Lievens (UGent) , Veerle Surmont (UGent) , Lieve Brochez (UGent) , Dries Reynders (UGent) , et al.

(2023) JAMA ONCOLOGY.

Add to list

Towards the discovery of prognostic and predictive biomarkers in CHEERS, a radioimmunotherapy phase II trial

Jan Vanwelkenhuyzen (UGent) , Mathieu Spaas (UGent) , Kim Van der Eecken (UGent) , Vibeke Kruse (UGent) , Sylvie Rottey (UGent) , Lieve Brochez (UGent) , Johan Lindberg, Katleen De Preter (UGent) , Bram De Laere (UGent) and Piet Ost (UGent)

(2022) OncoPoint Symposium 2022, Abstracts.

Add to list

Journal Article
A1
open access

Mental health and quality of life among patients with cancer during the SARS-CoV-2 pandemic : results from the longitudinal ONCOVID survey study

Emiel De Jaeghere (UGent) , Heini Kanervo (UGent) , Roos Colman (UGent) , Wim Schrauwen (UGent) , Paulien West (UGent) , Nele Vandemaele (UGent) , Aglaja De Pauw (UGent) , Celine Jacobs (UGent) , Ingeborg Hilderson, Michael Saerens (UGent) , et al.

(2022) CANCERS. 14(4).

Add to list

Journal Article
A1
open access

Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS) : study protocol for a phase 2, open-label, randomized controlled trial

Mathieu Spaas (UGent) , Nora Sundahl, Eva Hulstaert, Vibeke Kruse (UGent) , Sylvie Rottey (UGent) , Daan De Maeseneer (UGent) , Veerle Surmont (UGent) , Annabel Meireson (UGent) , Lieve Brochez (UGent) , Dries Reynders (UGent) , et al.

(2021) BMC CANCER. 21(1).

Add to list

Journal Article
A1
open access

Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures

Annabel Meireson (UGent) , Simon Tavernier (UGent) , Sofie Van Gassen (UGent) , Nora Sundahl, Annelies Demeyer (UGent) , Mathieu Spaas (UGent) , Vibeke Kruse (UGent) , Liesbeth Ferdinande (UGent) , Jo Van Dorpe (UGent) , Benjamin Hennart, et al.

(2021) CANCERS. 13(11).

Add to list

Selective oral MEK1/2 inhibitor pimasertib : a phase I trial in patients with advanced solid tumors

Jean-Pierre Delord, Antoine Italiano, Ahmad Awada, Philippe Aftimos, Nadine Houédé, Céleste Lebbé, Celine Pages, Thierry Lesimple, Monica Dinulescu, Jan H. M. Schellens, et al.

(2021) TARGETED ONCOLOGY. 16(1). p.37-46

Add to list

Selective oral MEK1/2 inhibitor pimasertib in metastatic melanoma : antitumor activity in a phase I, dose-escalation trial

Céleste Lebbé, Antoine Italiano, Nadine Houédé, Ahmad Awada, Philippe Aftimos, Thierry Lesimple, Monica Dinulescu, Jan H. M. Schellens, Suzanne Leijen, Sylvie Rottey (UGent) , et al.

(2021) TARGETED ONCOLOGY. 16(1). p.47-57

Add to list

Miscellaneous

Spatiotemporal evolution of radiation myositis on 18F-FDG PET/CT following hypofractionated radiotherapy of intramuscular melanoma metastases

Mathieu Spaas (UGent) , Bliede Van den Broeck (UGent) , David Creytens (UGent) , Vibeke Kruse (UGent) and Piet Ost (UGent)

(2021) CLINICAL NUCLEAR MEDICINE. 46(7). p.E384-E386

Add to list

Managing viral hepatitis in cancer patients under immune checkpoint inhibitors : should we take the risk?

Stijn De Keukeleire (UGent) , Tijl Vermassen (UGent) , Zahra Mosala Nezhad, Tessa Kerre (UGent) , Vibeke Kruse (UGent) , Hans Van Vlierberghe (UGent) , Karim Vermaelen (UGent) and Sylvie Rottey (UGent)

(2021) IMMUNOTHERAPY. 13(5). p.409-418

Add to list

A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

Yanina Jansen, Vibeke Kruse (UGent) , Jurgen Corthals, Kelly Schats, Pieter-Jan van Dam, Teofila Seremet, Carlo Heirman, Lieve Brochez (UGent) , Mark Kockx, Kris Thielemans, et al.

(2020) CANCER IMMUNOLOGY IMMUNOTHERAPY. 69(12). p.2589-2598

Academic Bibliography

prof. Vibeke Kruse

Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors The CHEERS Phase 2 Randomized Clinical Trial

Towards the discovery of prognostic and predictive biomarkers in CHEERS, a radioimmunotherapy phase II trial

Mental health and quality of life among patients with cancer during the SARS-CoV-2 pandemic : results from the longitudinal ONCOVID survey study

Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS) : study protocol for a phase 2, open-label, randomized controlled trial

Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures

Selective oral MEK1/2 inhibitor pimasertib : a phase I trial in patients with advanced solid tumors

Selective oral MEK1/2 inhibitor pimasertib in metastatic melanoma : antitumor activity in a phase I, dose-escalation trial

Spatiotemporal evolution of radiation myositis on 18F-FDG PET/CT following hypofractionated radiotherapy of intramuscular melanoma metastases

Managing viral hepatitis in cancer patients under immune checkpoint inhibitors : should we take the risk?

A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

Contents

Support

Contact